Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Seattle, Washington

This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11408
Shown on this page
12
Current sort
Recently updated
Location scope
Seattle, WA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Seattle, Washington. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 445–456 of 11,408 matching trials in Seattle, WA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Seattle

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Promoting Physical Activity in Older Hispanic/Latino(a) Adults

NCT06362824
Conditions
Sedentary Behavior, Physical Inactivity, Alzheimer Disease, Protection Against
Interventions
De Pie Intervention, Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
55 Years to 89 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Diego, California • Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Linvoseltamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
14
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 10 more
Conditions
Charcot Marie Tooth Disease
Interventions
Not listed
Lead sponsor
Michael Shy
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2030
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more
Conditions
Chronic Myelomonocytic Leukemia (CMML)
Interventions
Cobimetinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Portland, Oregon • Salt Lake City, Utah • Seattle, Washington
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
La Jolla, California • San Francisco, California • Evanston, Illinois + 6 more
Conditions
Moderately to Severely Active Crohns Disease
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
64
States / cities
Dothan, Alabama • Glendale, Arizona • Lancaster, California + 57 more
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Nadofaragene Firadenovec, Durvalumab, Gemcitabine, Cisplatin, Radical Cystectomy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
581
States / cities
Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more
Conditions
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Radiation Therapy
Other · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
552
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
Conditions
Symptoms and Signs, Cancer, Childhood Cancer
Interventions
Computerized Symptom Capture Tool (C-SCAT) Intervention, Usual Care Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 29 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Kansas City, Missouri • Salt Lake City, Utah • Richmond, Virginia + 1 more
Conditions
Stroke Recurrence, Myocardial Infarction, Vascular Death, Ischemic Stroke, TIA (Transient Ischemic Attack), Stroke (CVA) or Transient Ischemic Attack, Recurrent Stroke
Interventions
Cilostazol 100 mg Tablets, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
52
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 41 more
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
858
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more